News

Deal Announcements

Intellikine Collects $51 Million Venture Capital

Monday, July 13, 2009 5:58:00 AM PDT | VentureDeal Staff
La Jolla, California  --  Biotechnology company Intellikine has garnered $51 million in a new round of venture capital investment.

Intellikine discovers and develops small molecule therapies targeting the PI3K/Akt/mTOR pathway.

Investors in the round included Biogen Idec, US Venture Partners, FinTech Global and Novartis Venture Fund. Proceeds purposes from the round were not disclosed.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1